Jia Xin Yu

Has grant

Institute of Cancer Research

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Improving Sorafenib; a multi-targeted kinase inhibitor used for the treatment of hepatocellular carcinoma by mechanistically dissecting out its underlying targets and anti-targets

Open Date: 2016-07-08

Close Date: 2018-09-14

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Benjamin G. Vincent

University of North Carolina at Chapel Hill

UNITED STATES

View details

Lisa Anne Carey

University of North Carolina at Chapel Hill

UNITED STATES

View details

Yara G Abdou

University of North Carolina at Chapel Hill

UNITED STATES

View details

Jun Tang

Institute of Cancer Research

UNITED STATES

View details

Qi Long

Professor

University of Pennsylvania

UNITED STATES

View details

CHANGGEE CHANG

Assistant Professor

Indiana University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jia Xin Yu

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (15)

Unraveling relatlimab (RELA)-specific biology: Biomarker analyses in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) treated with 1L nivolumab (NIVO) + RELA high-dose (HD) and platinum-doublet chemotherapy (PDCT).

Unravelling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER

Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma.

LBA51 Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors

Circulating <i>KRAS</i> variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy.

Distinct biosignatures associate with survival after chemoimmunotherapy in a randomized, three-arm phase II study in patients with metastatic pancreatic cancer.

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Immuno-oncology drug development forges on despite COVID-19

CRI iAtlas: an interactive portal for immuno-oncology research

Cancer cell therapies: the clinical trial landscape.

Impact of COVID-19 on oncology clinical trials.

Trends in clinical development for PD-1/PD-L1 inhibitors.

Collaborators (6)

Benjamin G. Vincent

Lisa Anne Carey

Yara G Abdou

Jun Tang

Qi Long

CHANGGEE CHANG

Make your next move.